{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-323652","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2026-07-29T20:05:59+00:00","discovered_at":"2026-07-29T20:07:00.561217+00:00","generated_at":"2026-07-29T20:07:16.573317+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viking Q2 net loss $128M; Phase 3 obesity trials fully enrolled; cash $502M","bullets":["Net loss of $128.0M ($1.10/share) vs $65.6M ($0.58) in Q2 2025; R&D spend $115.8M.","Phase 3 VANQUISH-1 (4,500 patients) and VANQUISH-2 (1,000) for subcutaneous VK2735 fully enrolled.","Oral VK2735 Phase 3 trial initiation expected in Q4 2026; maintenance dosing data due Q3 2026.","Phase 1 trial of amylin agonist VK3019 initiated in Q2 2026 after IND clearance.","Appointed Hubert Chen, M.D., as CMO; Dorothy Gemmell to board; cash $502M at June 30."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-323652","json":"https://secwatch.observer/filing/0001193125-26-323652.json","markdown":"https://secwatch.observer/filing/0001193125-26-323652.md","text":"https://secwatch.observer/filing/0001193125-26-323652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/0001193125-26-323652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T20:07:16.573317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}